[Hemolytic and uremic syndrome and related thrombotic microangiopathies: Treatment and prognosis]

Details

Serval ID
serval:BIB_CAEF0C54AA4E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
[Hemolytic and uremic syndrome and related thrombotic microangiopathies: Treatment and prognosis]
Journal
Rev Med Interne
Author(s)
Rafat C., Coppo P., Fakhouri F., Fremeaux-Bacchi V., Loirat C., Zuber J., Rondeau E.
ISSN
1768-3122 (Electronic)
ISSN-L
0248-8663
Publication state
Published
Issued date
12/2017
Volume
38
Number
12
Pages
833-839
Language
english
Notes
Rafat, C
Coppo, P
Fakhouri, F
Fremeaux-Bacchi, V
Loirat, C
Zuber, J
Rondeau, E
fre
Review
France
Rev Med Interne. 2017 Dec;38(12):833-839. doi: 10.1016/j.revmed.2017.07.005. Epub 2017 Sep 22.
Abstract
Major achievements in the understanding of thrombotic microangiopathies (TMA) have not only resulted in a reclassification of TMA but most of all they have culminated in the design of new treatments and have enabled clinicians to better delineate their prognosis. Recent multicenter studies have improved our understanding of the prognosis of atypical hemolytic and uremic syndromes (aHUS). More specifically, they have highlighted the role of genetic testing on predicting the recurrence of aHUS, the risk of chronic kidney disease and the recurrence following kidney transplantation. A major advance consisted of the identification of the alternative complement pathway in the pathogenesis of aHUS, thus paving the way for the use of the C5a inhibitor eculizumab in this indication. Eculizumab has thereafter dramatically improved the management of patients affected with aHUS. During spring 2011, a great epidemic of entero-hemorrhagic Escherichia coli (EHEC) associated HUS occurred in Germany, providing clinicians the opportunity to examine the relevance of antibiotic prophylaxis, plasma exchange and eculizumab in EHEC-associated HUS. In this work, we herein present advances achieved in the setting of therapeutic management and prognosis in HUS and other related TMA syndromes.
Keywords
Dysentery, Bacillary/complications/diagnosis/therapy, Enterohemorrhagic Escherichia coli/pathogenicity, Escherichia coli Infections/complications/diagnosis/therapy, Hemolytic-Uremic Syndrome/*diagnosis/epidemiology/*therapy, Humans, Pneumococcal Infections/complications/diagnosis/therapy, Prognosis, Shigella dysenteriae/pathogenicity, Thrombotic Microangiopathies/*diagnosis/epidemiology/*therapy, Vitamin B 12 Deficiency/complications/diagnosis/therapy, Eculizumab, Hemolytic and uremic syndrome, Kidney transplantation, Microangiopathie thrombotique, Plasmapheresis, Plasmapherese, Syndrome hemolytique et uremique, Thrombotic microangiopathy, Transplantation renale
Pubmed
Create date
01/03/2022 11:18
Last modification date
02/03/2022 7:36
Usage data